SARS-CoV-2 vs. SARS-CoV-1 management: antibiotics and inflammasome modulators potential

Area of Science:

• Virology
• Immunology
• Public Health

Background:

• SARS-CoV-2, causing COVID-19, shares genetic and symptomatic similarities with SARS-CoV-1 (2003 SARS).
• Both diseases present symptoms akin to community-acquired pneumonia.
• Initial SARS treatment involved antibiotics, contrasting with the COVID-19 pandemic's global shutdown strategy.

Purpose of the Study:

• To explore therapeutic strategies for severe COVID-19 by examining the shared pathogenic mechanisms with SARS.
• To investigate the role of inflammasome activation in cytokine storm development for both viruses.
• To identify safer alternatives to corticoids for managing severe COVID-19 inflammation.

Main Methods:

• Comparative genetic analysis of SARS-CoV-2 and SARS-CoV-1.
• Review of clinical manifestations and treatment strategies for SARS and COVID-19.
• Examination of the inflammasome pathway's role in cytokine storm pathogenesis.

Main Results:

• SARS-CoV-2 and SARS-CoV-1 exhibit over 70% genetic similarity.
• Severe cases of both SARS and COVID-19 feature a cytokine storm mediated by inflammasome activation.
• Corticoids, while used, have significant side effects limiting their application.

Conclusions:

• The shared inflammasome activation pathway in SARS and COVID-19 suggests potential therapeutic targets.
• Anti-inflammasome agents present a promising, potentially safer alternative to corticoids for severe COVID-19.
• Understanding these shared mechanisms is crucial for effective pandemic management and treatment development.